Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Larimar Therapeutics, Inc. LRMR

14 fiscal years on record · USD · FY2025 reported · SEC filings only
$-165.7M
$-113.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 14-year series below
Revenue $M Net income $M
FY2019 · Revenue 0.0 · Net income -23.1
-30M-60M
201220152018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -132.6%
-50%-100%-150%
201220182025
Three returns, three denominators.

Each USD of equity lost 133 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -113.3
-50M-100M
201220182025

Total assetsUSD 145.8M
EquityUSD 78.1M
CashUSD 85.4M
Current ratio2.19×

Equity funds 54% of total assets.

The 14-year record

14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
LRMR, 14-year financial record
Metric 20252024202320222021202020192018201720162015201420132012
Revenue $B◌◌◌◌◌◌0.00.00.00.00.00.00.00.0
Operating income $B−0.2−0.1−0.0−0.0−0.1−0.0−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.2−0.1−0.0−0.0−0.1−0.0−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Net income $B−0.2−0.1−0.0−0.0−0.1−0.0−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.1−0.1−0.0−0.0−0.0
EPS, diluted $◌−1.32−0.84−1.37−2.95−3.57−3.80−1.90−1.90−2.12−2.78−3.00−19.53−19.65
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————
ROE %−132.6−63.6−38.4−40.3−65.7——−151.3−52.0−39.8−54.3———
Shares out B0.080.060.040.040.020.020.040.040.030.030.030.020.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 53 reconciliationsAUDITED

Reconciled in 14 of the 14 fiscal years we could check. 12 checks were skipped: the balance sheet is not tagged before 2013. Five checks were skipped: EPS is not tagged before 2012.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2012

Share this section

Download image